Figure 3.
DNA methylation and cell-cycle analysis of immune cells from patients receiving T-reg graft and SOC. (A) FOXP3 TSDR (left) and non-TSDR (right) methylation from patient whole-blood DNA collected on day 14 or 30 after transplantation from patients who received transplant with T-reg graft alone (n = 12) or T-reg graft with single-agent prophylaxis (n = 12) and compared with a contemporaneous SOC cohort (n = 11). (B) Principal component analysis and 95% confidence ellipses of cell-cycle gene expression in sorted CD4+ Tcon and CD4+ Treg from day 14 after transplantation (left) and table summarizing the number of samples according to the group and cell type identified as most closely associated with G1, G2M, or S-phase of the cell cycle (right) (SOC, n = 7; no PPX, n = 12; and PPX, n = 9). (C) Regenerating islet–derived protein 3α and suppression of tumorigenicity 2 (ST2) serum concentrations on day 7 after HCT ∗ P ≤ .05, ∗∗ P ≤ .01; ns, not significant.

DNA methylation and cell-cycle analysis of immune cells from patients receiving T-reg graft and SOC. (A) FOXP3 TSDR (left) and non-TSDR (right) methylation from patient whole-blood DNA collected on day 14 or 30 after transplantation from patients who received transplant with T-reg graft alone (n = 12) or T-reg graft with single-agent prophylaxis (n = 12) and compared with a contemporaneous SOC cohort (n = 11). (B) Principal component analysis and 95% confidence ellipses of cell-cycle gene expression in sorted CD4+ Tcon and CD4+ Treg from day 14 after transplantation (left) and table summarizing the number of samples according to the group and cell type identified as most closely associated with G1, G2M, or S-phase of the cell cycle (right) (SOC, n = 7; no PPX, n = 12; and PPX, n = 9). (C) Regenerating islet–derived protein 3α and suppression of tumorigenicity 2 (ST2) serum concentrations on day 7 after HCT ∗ P ≤ .05, ∗∗ P ≤ .01; ns, not significant.

Close Modal

or Create an Account

Close Modal
Close Modal